Vol 6 Issue 9

New horizons in cellular immunotherapy: next-gen platforms and modalities

Oct 2020

Guest Editor:

David Morrow, Scientific Programme Manager, Translational Medicine & Drug Development at EATRIS

Expert Insight

Temferon™, an <em>ex-vivo</em> genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Stefania Mazzoleni,

Bernhard Gentner,

Valentina Brambilla,

Tiziana Magnani,

Fabio Ciceri,

Gaetano Finocchiaro,

Luigi Naldini,

Carlo Russo

13 November 2020

Expert Insight

Engineering precision cell therapy for immune-mediated disease

Michael Milone,

Gwendolyn Binder

27 October 2020

Expert Insight

From a clinician’s perspective: road to safer CAR-T cell immunotherapies

Chenggong Li,

Heng Mei

20 October 2020

Expert Insight

Immunological tolerance: scanning a barren landscape for signs of sustained growth

Harry Petropoulos,

Timothy J Davies,

Paul J Fairchild

28 September 2020

Expert Insight

Innovator Insight

Evolving the role of gene editing in cell therapy

Jonathan Frampton,

Torsten Meissner,

Tristan Thwaites

29 October 2020

Innovator Insight

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

Rebuma Firdessa-Fite,

Jorge Postigo-Fernandez,

Valérie Toussaint-Moreau,

Fabrice Stock,

Dr Alengo Nyamay’antu,

Patrick Erbacher ,

Rémi Creusot

29 October 2020

Innovator Insight

The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies

Vicki Moignard,

Alessandra De Riva,

Raul Elgueta

29 October 2020

Innovator Insight

Commentary

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

David Morrow,

Jan Langermans,

Anton Ussi,

Antonio Andreu,

Lucia Gabriele

20 October 2020

Commentary

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

David Gilham

22 September 2020

Commentary

Interview

Driving lupus out with CARs

Marko Radic

22 October 2020

Interview

Regulatory Insight

FDA perspective on the preclinical development of cell-based immunotherapies

Alyssa Kosmides Galaro,

Christopher Saeui

23 October 2020

Regulatory Insight

Investor Insights October 2020

Commentary

Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Shyam Patel,

Sohel Talib,

Maria Millan

5 October 2020

Commentary

Interview

Driving disruptive innovation in the ATMP field

Kerstin Papenfuss

6 October 2020

Interview

Clinical Trends October 2020

Commentary

Major clinical stories and read-outs from key conferences for the cell and gene therapy space

Sven Kili

25 November 2020

Commentary

Editorial

Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Chris Mason

22 October 2020

Editorial

Expert Insight

Process development and scale-up of pluripotent stem cell manufacturing

Shuohao Huang,

Azher Razvi,

Zoe Anderson-Jenkins,

Danylo Sirskyj,

Ming Gong,

Anne-Marie Lavoie,

Gary Pigeau

22 October 2020

Expert Insight

Evolving the role of gene editing in cell therapy

Jonathan Frampton, Horizon Discovery at Horizon Discovery

Tristan Thwaites, Lead Technical Scientist at Cell and Gene Therapy Catapult

Torsten Meissner, Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology at Harvard Medical School

6 October 2020

Webinar

Watch now

Scalable AAV manufacturing – Addressing challenges across the workflow

Kenneth Thompson, Manager, R&D, Cell Biology at Thermo Fisher Scientific

Dr Chao Yan Liu, Senior Manager, R&D, Cell Biology Thermo Fisher Scientific

John Li, Staff Scientist at Thermo Fisher Scientific

Michael Brewer, Director, Global Principal Consultant, Regulatory, BioProduction at Thermo Fisher Scientific

29 October 2020

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Oct 2020. Vol 6 Issue 9

FEATURING

Spotlight

New horizons in cellular immunotherapy: next-gen platforms and modalities

Expert Insight

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Engineering precision cell therapy for immune-mediated disease

From a clinician’s perspective: road to safer CAR-T cell immunotherapies

Immunological tolerance: scanning a barren landscape for signs of sustained growth

Innovator Insight

Evolving the role of gene editing in cell therapy

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies

Commentary

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Interview

Driving lupus out with CARs

Regulatory Insight

FDA perspective on the preclinical development of cell-based immunotherapies

Report

Investor Insights October 2020

Commentary

Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Interview

Driving disruptive innovation in the ATMP field

Report

Clinical Trends October 2020

Commentary

Major clinical stories and read-outs from key conferences for the cell and gene therapy space

Other articles

Editorial

Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Expert Insight

Process development and scale-up of pluripotent stem cell manufacturing

Webinars

Evolving the role of gene editing in cell therapy

Scalable AAV manufacturing – Addressing challenges across the workflow

CELL & GENE THERAPY INSIGHTS

Oct 2020. Vol 6 Issue 9

FEATURING

Spotlight

New horizons in cellular immunotherapy: next-gen platforms and modalities

Sponsor

Expert Insight

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Engineering precision cell therapy for immune-mediated disease

From a clinician’s perspective: road to safer CAR-T cell immunotherapies

Immunological tolerance: scanning a barren landscape for signs of sustained growth

Innovator Insight

Evolving the role of gene editing in cell therapy

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies

Commentary

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Interview

Driving lupus out with CARs

Regulatory Insight

FDA perspective on the preclinical development of cell-based immunotherapies

Report

Investor Insights October 2020

Commentary

Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Interview

Driving disruptive innovation in the ATMP field

Report

Clinical Trends October 2020

Commentary

Major clinical stories and read-outs from key conferences for the cell and gene therapy space

Other articles

Editorial

Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Expert Insight

Process development and scale-up of pluripotent stem cell manufacturing

Webinars

Evolving the role of gene editing in cell therapy

Scalable AAV manufacturing – Addressing challenges across the workflow